PYXS
Pyxis Oncology, Inc.
Pyxis Oncology, Inc. insider trading
Pyxis Oncology, Inc. is on this site because an insider bought its stock on the open market in the last 30 days. Every open-market purchase and sale its officers, directors and 10% owners filed in that time is listed below, each linked to the original Form 4.
From SEC filings · last 30 days
Recent PYXS insider transactions
No open-market purchases or sales are left in the 30-day window for this company. Grants and option exercises are not counted as trades.
SEC Form 4 data, Q3 2024 to Q2 2026
PYXS insider trading by quarter
Between Jul 01, 2024 and Jun 30, 2026, 2 insiders traded PYXS on the open market: 2 purchases worth $174.4K and 3 sales worth $15.9K, every sale pre-scheduled under a 10b5-1 plan. In the last four quarters alone: no open-market trades at all.
| Quarter | Bought | Sold | Insiders |
|---|---|---|---|
| Q2 2026 | — | — | |
| Q1 2026 | — | — | |
| Q4 2025 | — | — | |
| Q3 2025 | — | — | |
| Q2 2025 | — | −$15.9K3 sales · all on a plan | |
| Q1 2025 | — | — | |
| Q4 2024 | +$174.4K2 buys | — | |
| Q3 2024 | — | — |
- Largest purchase
- +$163.5K of PYXS by Connealy Pamela Ann (CFO & COO) on Nov 26, 2024.
- Largest sale
- −$14.3K of PYXS by Humphrey Rachel (Director) on Apr 21, 2025, under a 10b5-1 plan.
Open-market transactions through Jun 30, 2026most recent first
Humphrey Rachel10b5-1
Director
−$14.3K
Apr 21, 2025
13,896 sh · $1.03
Humphrey Rachel10b5-1
Director
−$194
Apr 17, 2025
200 sh · $0.97
Humphrey Rachel10b5-1
Director
−$1.4K
Apr 14, 2025
1,400 sh · $0.97
Connealy Pamela Ann
CFO & COO
+$163.5K
Nov 26, 2024
83,400 sh · $1.96
Connealy Pamela Ann
CFO & COO
+$10.9K
Nov 26, 2024
5,450 sh · $2.00
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Apr 21, 2025 | Humphrey Rachel10b5-1Director | 13,896 | $1.03 | −$14.3K |
| Apr 17, 2025 | Humphrey Rachel10b5-1Director | 200 | $0.97 | −$194 |
| Apr 14, 2025 | Humphrey Rachel10b5-1Director | 1,400 | $0.97 | −$1.4K |
| Nov 26, 2024 | Connealy Pamela AnnCFO & COO | 83,400 | $1.96 | +$163.5K |
| Nov 26, 2024 | Connealy Pamela AnnCFO & COO | 5,450 | $2.00 | +$10.9K |
From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.
Don't check PYXS — let it ping you
Watch every insider filing the minute it clears the SEC
The live dashboard reads every Form 4 as it lands and puts it in plain English — open-market buys, cluster buys where several insiders move at once, and the sales executives chose to make rather than scheduled. Free to open; Pro adds alerts, watchlists and each buyer's track record.
Pyxis Oncology, Inc. is outside the 777 companies InsiderPulse scans continuously. This page is built from the filings on the live tape and stays up while its insiders are buying. Monitoring, not advice.
Other companies insiders are buying now
Questions
- Have PYXS insiders bought or sold stock recently?
- No open-market purchases or sales by Pyxis Oncology, Inc. insiders appear in the Form 4 filings scanned for this page. Grants, option exercises and tax withholding are not counted as trades.
- How much PYXS stock have insiders bought and sold in the last two years?
- Between Jul 01, 2024 and Jun 30, 2026, 2 Pyxis Oncology, Inc. insiders made 2 open-market purchases worth $174.4K and 3 sales worth $15.9K. Every one of the sales was pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: no purchases and no sales. The largest purchase was Connealy Pamela Ann buying $163.5K on Nov 26, 2024. The largest sale was Humphrey Rachel selling $14.3K on Apr 21, 2025.
- When did an insider last buy PYXS shares?
- The most recent open-market purchase in SEC's data through Jun 30, 2026 is Connealy Pamela Ann (CFO & COO) buying $163.5K on Nov 26, 2024.
- Where does PYXS insider trading data come from?
- From the Form 4 filings Pyxis Oncology, Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.
Get the free Insider Brief
Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.